Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 2 of 16
The Nobel committee honored work that identified channelrhodopsin and then adapted it to switch selected neurons on and off with light in living brains. The prize highlights how a basic-science finding in algae became a widely used method for mapping how specific cells shape behavior, memory and disease-relevant circuitry.
Oct 5, 2026In the phase 3 Opus-1 study, VAX-31 showed non-inferiority on all 20 strains targeted by Prevnar 20 and 17 of the 19 serotypes targeted by Capvaxive. The two misses against Capvaxive still cleared a lower historical non-inferiority threshold, leaving Vaxcyte with a competitive dataset in a market where serotype coverage tradeoffs define product positioning.
Oct 5, 2026The startup is combining lipid nanoparticle delivery, messenger RNA, a CD161-targeting antibody and the cGAS-STING pathway in an effort to create a more selective immunology therapy. Its pitch is that precision depletion of disease-driving cells could avoid some tradeoffs associated with broader immune reset approaches and cell therapies.
Ahead of this year’s Nobel announcements, geneticist Mary-Claire King reflected on a long period of being mentioned as a possible winner and on the work that put her in that conversation. King’s identification of hereditary breast and ovarian cancer risk linked to BRCA1 and BRCA2 helped create actionable prevention pathways that she said have saved thousands of women from cancer mortality.
Oct 2, 2026The package arrives amid political attacks on women’s rights and health care and funding cuts affecting this area of research, according to the editors. Its deeper message is that women’s health is still often funded and studied too narrowly, leaving basic questions unresolved even in conditions with a large patient burden.
Sep 30, 2026The randomized, double-blind, placebo-controlled study enrolled 149 patients with moderate to severe hidradenitis suppurativa. The key industry signal is portfolio breadth: Merck now has support for moving tulisokibart into Phase 3 in HS even after mixed readouts in other inflammatory diseases.
Sep 30, 2026Amgen’s abstract and presentation at the European Academy of Dermatology and Venereology Congress in Milan add specificity to a result the company had previously described only in broad terms. For a company that had seen daxdilimab fail in systemic lupus erythematosus and had dropped two internal midstage lupus programs for futility, the discoid lupus signal matters less as a broad lupus comeback than as evidence that a narrower dermatology indication may still support the asset.
Sep 30, 2026The study, published in Neuron, used an antibody to block CXCR3 in mice modeling Alzheimer’s disease and other tauopathies. Treated animals showed less brain tissue loss and better performance on standard memory tests even though tau levels were similar between treated and untreated groups.
Sep 29, 2026Research published in the Proceedings of the National Academy of Sciences suggests the aftermath of the 2023 Maui wildfires left nearby residents exposed to metal mixtures associated with respiratory harm long after the burning stopped. The work adds evidence that climate-related disasters can create chronic exposure pathways through burned buildings, vehicles, electronics and contaminated residue, not just vegetation smoke.
Sep 28, 2026The DAYBREAK study put two Kodiak candidates against aflibercept in wet age-related macular degeneration and met the primary endpoint on vision gains at one year. The more immediate commercial readthrough centers on zenkuda, where Kodiak is pitching Eylea-like efficacy with longer intervals between treatments for many patients.
Sep 28, 2026One year after treatment, 12 of 22 evaluated patients had achieved remission of lupus symptoms, and eight of 16 patients with lupus nephritis had remission of kidney symptoms. The readout gives Adicet a differentiated position in autoimmune CAR-T as recent safety events have disrupted competing CD19 programs.
Sep 27, 2026The method uses cholesterol-conjugated, photocleavable hashtag oligonucleotides and patterned light exposure to stamp spatial coordinates onto individual cells before single-cell multiome sequencing. The strategic signal is less about a single biological finding than about a modular workflow that aims to narrow the tradeoff between spatial context and scalable single-cell readouts.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.